Predicted to enable several functions, including PDZ domain binding activity; metallopeptidase activity; and signaling receptor binding activity. Involved in several processes, including positive regulation of ERK1 and ERK2 cascade; regulation of apoptotic process; and response to antineoplastic agent. Located in apical part of cell and cell surface. Biomarker of Alzheimer's disease; congestive heart failure; and thoracic aortic aneurysm. Human ortholog(s) of this gene implicated in Alzheimer's disease; inflammatory bowel disease; and type 2 diabetes mellitus. Orthologous to human ADAM17 (ADAM metallopeptidase domain 17); PARTICIPATES IN epidermal growth factor/neuregulin signaling pathway; interleukin-6 signaling pathway; Notch signaling pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 2,6-dinitrotoluene; 2-amino-2-deoxy-D-glucopyranose.
a disintegrin and metallopeptidase domain 17; a disintegrin and metalloprotease domain 17; a disintegrin and metalloproteinase domain 17; a disintegrin and metalloproteinase domain 17 (tumor necrosis factor, alpha, converting enzyme); ADAM 17; disintegrin and metalloproteinase domain-containing protein 17; TACE; TNF-alpha convertase; TNF-alpha converting enzyme; TNF-alpha-converting enzyme
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA] and IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA
4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ADAM17 protein] and 4-phenylbutyric acid inhibits the reaction [SFTPC protein mutant form results in increased expression of ADAM17 protein]
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA] and IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of ADAM17 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of ADAM17 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA
pyrazolanthrone inhibits the reaction [hydroquinone results in increased expression of ADAM17 protein] and pyrazolanthrone inhibits the reaction [hydroquinone results in increased expression of and results in increased stability of ADAM17 mRNA]
Glucosamine inhibits the reaction [IL1B results in increased expression of ADAM17 mRNA] and IL1B affects the reaction [Glucosamine results in increased expression of ADAM17 mRNA]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA and [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA and [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA
polyethylene glycol-superoxide dismutase inhibits the reaction [Cyclosporine results in increased activity of ADAM17 protein] and polyethylene glycol-superoxide dismutase inhibits the reaction [Cyclosporine results in increased phosphorylation of ADAM17 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA
Diosgenin inhibits the reaction [Streptozocin results in increased expression of ADAM17 mRNA] and Diosgenin inhibits the reaction [Streptozocin results in increased expression of ADAM17 protein]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA and [bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of ADAM17 mRNA
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [hydroquinone results in increased expression of ADAM17 protein] more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA
4-methylumbelliferone 8-carbaldehyde inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ADAM17 protein] and 4-phenylbutyric acid inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ADAM17 protein]
[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ADAM17 mRNA
ADAM17 protein affects the reaction [Tetradecanoylphorbol Acetate results in increased secretion of HBEGF protein] and ADAM17 protein affects the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TGFA protein]
[Rosmarinic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which affects the localization of PROCR protein more ...
[Rosmarinic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which affects the localization of PROCR protein more ...
Diosgenin inhibits the reaction [Streptozocin results in increased expression of ADAM17 mRNA] and Diosgenin inhibits the reaction [Streptozocin results in increased expression of ADAM17 protein]
Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans.